Table 1C.
Characteristics of incident cancer patients treated with epoetin or transfusion before and after June 2008
| Cohort entry before June 2008n = 48 341 | Cohort entry after June 2008n = 21 547 | |||||
|---|---|---|---|---|---|---|
| Epoetins n = 1934 | Transfusions n = 42 848 | Epoetins and transfusions n = 3559 | Epoetins n = 715 | Transfusions n = 20 005 | Epoetins and transfusions n = 827 | |
| Median age at cohort entry (Q1, Q3) | 60 (49, 68) | 69 (61, 78) | 66 (57, 72) | 61 (50, 71) | 70 (61, 78) | 67 (57, 72) |
| Assessment of cancer | ||||||
| Via diagnoses only | 292 (15.1%) | 31 878 (74.4%) | 1690 (47.5%) | 134 (18.7%) | 14 141 (70.7%) | 346 (41.8%) |
| Via diagnoses and therapy | 1568 (81.1%) | 10 533 (24.6%) | 1789 (50.3%) | 541 (75.7%) | 5660 (28.3%) | 449 (54.3%) |
| Via therapy only | 74 (3.8%) | 437 (1.0%) | 80 (2.2%) | 40 (5.6%) | 204 (1.0%) | 32 (3.9%) |
| Cancer with unfavourable prognosis * | 273 (14.1%) | 10 668 (24.9%) | 928 (26.1%) | 84 (11.8%) | 5182 (25.9%) | 261 (31.6%) |
| Chronic kidney disease | 326 (16.9%) | 7606 (17.8%) | 1009 (28.4%) | 181 (25.3%) | 4066 (20.3%) | 273 (33.0%) |
| Median value of CCI ** (Q1, Q3) | 5 (2, 8) | 6 (3, 9) | 8 (4, 9) | 7 (3, 9) | 7 (3, 9) | 8 (4, 9) |